Research & Development

Can Geneoscopy's ColoSense Revolutionize Colorectal Cancer Screening?
Research & Development Can Geneoscopy's ColoSense Revolutionize Colorectal Cancer Screening?

Geneoscopy, Inc., a life sciences company dedicated to advancing gastrointestinal health, has recently achieved an impressive milestone by securing a Series C funding round that amassed $105 million. This significant investment, led by Bio-Rad Laboratories and supported by various prominent

Can Automation Boost Stem Cell Therapy Production for Parkinson's Disease?
Research & Development Can Automation Boost Stem Cell Therapy Production for Parkinson's Disease?

In a groundbreaking partnership aimed at revolutionizing the production processes for stem cell-based therapies, Mytos has joined forces with Aspen Neuroscience to enhance the manufacturing of autologous dopaminergic neuronal precursor cells (DANPCs). These cells are integral to Aspen’s ANPD001, an

Can AI Transform Undruggable Targets in Cancer Treatment?
Research & Development Can AI Transform Undruggable Targets in Cancer Treatment?

The field of drug discovery has long been challenged by the concept of "undruggable" targets—proteins and pathways that are crucial in disease processes but difficult to target with traditional small molecule drugs. One particularly challenging target is β-catenin, a key player in the Wnt/β-catenin

AI Wearable Cameras Revolutionize Detection of Medication Errors
Research & Development AI Wearable Cameras Revolutionize Detection of Medication Errors

The healthcare industry is witnessing an unprecedented advancement with the introduction of AI-powered wearable cameras designed to detect and prevent medication errors. These errors are a significant concern, contributing to a substantial number of preventable harms, with medication errors alone

Targeting Endocan: A New Hope for Treating Aggressive Brain Cancer
Research & Development Targeting Endocan: A New Hope for Treating Aggressive Brain Cancer

Glioblastoma, an aggressive and often fatal form of brain cancer, has long posed a formidable challenge to medical professionals. With an average lifespan of 12 to 15 months post-diagnosis and a mere 5% survival rate five years after diagnosis, the need for innovative treatments has never been more

How Does Penn Medicine Transform Cancer Treatment with CAR T Therapy?
Research & Development How Does Penn Medicine Transform Cancer Treatment with CAR T Therapy?

Penn Medicine’s Center for Cellular Immunotherapies (CCI) is at the forefront of revolutionizing cancer treatment through CAR (chimeric antigen receptor) T cell therapy. This innovative approach harnesses the power of the patient’s own immune system to target and destroy cancer cells, offering new

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later